TARO News and Press, Taro Pharmaceutical Industries Ltd. From 04/06/20

Taro Pharmaceutical Industries Ltd. (NYSE: TARO) (“Taro” or the “Company”) today announced the appointment of Daphne Huang as Vice President, CFO and Chief Accounting Officer, effective today. Ms. Huang has over 20 years of senior executive experience in financ...

The FDA is requesting all manufacturers of ranitidine drugs to withdraw them immediately from the U.S. market due to the presence of an impurity called N-Nitrosodimethylamine (NDMA), a suspected carcinogen. More news on: GlaxoSmithKline plc, Amneal Pharmaceuticals, Inc., Mylan N.V., Heal...

Taro Pharmaceuticals U.S.A., Inc. (“Taro” or the “Company”) is voluntarily recalling two (2) lots of Phenytoin Oral Suspension USP, 125 mg/5 mL both in 237 mL bottles, to the consumer level. Phenytoin Oral Suspension USP, 125 mg/5 mL is indicated for the treatment ...

Original Post Editor's Note : The summary bullets for this article were chosen by Seeking Read more ...

Taro Pharmaceutical Industries ( TARO -4% ) fiscal Q3 results : More news on: Taro Pharmaceutical Industries Ltd., Healthcare stocks news, Stocks on the move, Earnings news and commentary, Read more ...

Taro Pharmaceutical (NYSE: TARO ): Q3 GAAP EPS of $1.76 beats by $0.22 . More news on: Taro Pharmaceutical Industries Ltd., Earnings news and commentary, Healthcare stocks news, Read more ...

Taro Pharmaceutical Industries Ltd. (NYSE: TARO) (“Taro” or the “Company”) today provided unaudited financial results for the three and nine months ended December 31, 2019. Quarter ended December 31, 2019 Highlights ─ compared to December 31, 2018 ...

Taro Pharmaceutical Industries Ltd. (NYSE: TARO) announced today that it plans to release its financial results for the quarter and nine months ended December 31, 2019, after the close of market on Monday, February 3, 2020. The release will be accessible on Taro’s website at www.t...

(NDC 51672-4131-1) Lot # 331771 (Expiration June 2021) Due to Cross-Contamination With Enalapril Maleate Taro Pharmaceuticals U.S.A., Inc. (“Taro” or the “Company”) is voluntarily recalling one (1) lot of Lamotrigine 100 mg Tablets, Lot # 331771 (expir...

Taro Pharmaceutical Industries Ltd. (NYSE:TARO) (“Taro” or the “Company”) today announced the final results of its modified “Dutch auction” tender offer to repurchase up to $225 million in value of its ordinary shares, nominal (par) value NIS 0.0001 p...